» Articles » PMID: 19291315

Effects of Statins on the Secretion of Human Serum Albumin in Cultured HepG2 Cells

Overview
Journal J Biomed Sci
Publisher Biomed Central
Specialty Biology
Date 2009 Mar 18
PMID 19291315
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Statins reduce cholesterol biosynthesis by inhibiting HMG-CoA reductase and thereby lower total cholesterol and LDL cholesterol levels in serum, which in turn lower the incidence of cardiovascular disease (CVD). Statins are also known to modulate various cellular functions such as gene expression, cell proliferation, and programmed cell death through inhibition of downstream intermediates in cholesterol synthesis. In this study, we have investigated the possible effects of statins on the secretion of serum albumin from cultured HepG2 cells since high levels of serum albumin are associated with reduced risks for CVD and statins are effective in lowering the risk of CVD through other effects in addition to their effects on serum total cholesterol and LDL cholesterol levels, known as pleiotropic effects. Our results showed that simvastatin increased HSA secretion up to 32.3% compared to the control group. Among 3 statin analogs we tested, simvastatin exhibited the highest stimulatory effects on HSA secretion compared to the control group. Our study also showed that the increased HSA secretions from HepG2 cells by simvastatin treatments were due to the increased rate of HSA synthesis, not due to the reduced posttranslational degradation rate of HSA. Our finding suggests another added benefit of statins' treatments in preventing CVD through stimulation of HSA biosynthesis.

Citing Articles

Serum Albumin Levels: A Biomarker to Be Repurposed in Different Disease Settings in Clinical Practice.

Gremese E, Bruno D, Varriano V, Perniola S, Petricca L, Ferraccioli G J Clin Med. 2023; 12(18).

PMID: 37762957 PMC: 10532125. DOI: 10.3390/jcm12186017.


Alkaline phosphatase-to-albumin ratio as a novel predictor of long-term adverse outcomes in coronary artery disease patients who underwent PCI.

Dai X, Zheng Y, Tang J, Wang W, Guo Q, Yin S Biosci Rep. 2021; 41(7).

PMID: 34121126 PMC: 8243337. DOI: 10.1042/BSR20203904.


Chronic polypharmacy impairs explorative behavior and reduces synaptic functions in young adult mice.

Eroli F, Johnell K, Latorre Leal M, Adamo C, Hilmer S, Wastesson J Aging (Albany NY). 2020; 12(11):10147-10161.

PMID: 32445552 PMC: 7346056. DOI: 10.18632/aging.103315.


TAT-MTS-MCM fusion proteins reduce MMA levels and improve mitochondrial activity and liver function in MCM-deficient cells.

Erlich-Hadad T, Hadad R, Feldman A, Greif H, Lictenstein M, Lorberboum-Galski H J Cell Mol Med. 2017; 22(3):1601-1613.

PMID: 29265583 PMC: 5824393. DOI: 10.1111/jcmm.13435.


Impact of serum albumin levels on long-term outcomes in patients undergoing percutaneous coronary intervention.

Wada H, Dohi T, Miyauchi K, Shitara J, Endo H, Doi S Heart Vessels. 2017; 32(9):1085-1092.

PMID: 28429111 DOI: 10.1007/s00380-017-0981-8.


References
1.
Istvan E . Statin inhibition of HMG-CoA reductase: a 3-dimensional view. Atheroscler Suppl. 2003; 4(1):3-8. DOI: 10.1016/s1567-5688(03)00003-5. View

2.
Istvan E, Deisenhofer J . The structure of the catalytic portion of human HMG-CoA reductase. Biochim Biophys Acta. 2000; 1529(1-3):9-18. DOI: 10.1016/s1388-1981(00)00134-7. View

3.
Edwards J, Moore R . Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials. BMC Fam Pract. 2004; 4:18. PMC: 317299. DOI: 10.1186/1471-2296-4-18. View

4.
Bonn V, Cheung R, Chen B, Taghibiglou C, Van Iderstine S, Adeli K . Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytes. Atherosclerosis. 2002; 163(1):59-68. DOI: 10.1016/s0021-9150(01)00754-7. View

5.
LaRosa J, Grundy S, Waters D, Shear C, Barter P, Fruchart J . Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352(14):1425-35. DOI: 10.1056/NEJMoa050461. View